RELEVANT Trademark

Trademark Overview

On Friday, May 27, 2011, a trademark application was filed for RELEVANT with the United States Patent and Trademark Office. The USPTO has given the RELEVANT trademark a serial number of 85332661. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 29, 2013. This trademark is owned by Celgene Corporation. The RELEVANT trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research, namely, conducting clinical trials; conducting clinical trials for testing the safety and effectiveness of rituximab and lenalidomide
relevant

General Information

Serial Number85332661
Word MarkRELEVANT
Filing DateFriday, May 27, 2011
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 29, 2013
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2011

Trademark Statements

Goods and ServicesMedical and scientific research, namely, conducting clinical trials; conducting clinical trials for testing the safety and effectiveness of rituximab and lenalidomide

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 2, 2011
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Monday, July 29, 2013ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, July 29, 2013ABANDONMENT - NO USE STATEMENT FILED
Saturday, November 17, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 16, 2012EXTENSION 2 GRANTED
Wednesday, November 14, 2012EXTENSION 2 FILED
Thursday, November 15, 2012CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 14, 2012TEAS EXTENSION RECEIVED
Tuesday, June 12, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 8, 2012EXTENSION 1 GRANTED
Friday, June 8, 2012EXTENSION 1 FILED
Friday, June 8, 2012TEAS EXTENSION RECEIVED
Tuesday, December 27, 2011NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 1, 2011OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 1, 2011PUBLISHED FOR OPPOSITION
Tuesday, September 27, 2011LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, September 26, 2011ASSIGNED TO LIE
Wednesday, September 14, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 14, 2011EXAMINER'S AMENDMENT ENTERED
Wednesday, September 14, 2011NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, September 14, 2011EXAMINERS AMENDMENT E-MAILED
Wednesday, September 14, 2011EXAMINERS AMENDMENT -WRITTEN
Tuesday, September 13, 2011NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 13, 2011NON-FINAL ACTION E-MAILED
Tuesday, September 13, 2011NON-FINAL ACTION WRITTEN
Tuesday, September 13, 2011ASSIGNED TO EXAMINER
Thursday, June 2, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, May 31, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

relevant trials conducting clinical effectiveness rituximab lenalidomide safety testing research medical